APAC CRO Market A deep dive into the trends transforming APAC CRO industry P86A-52 June 2015
APAC CRO MarketA deep dive into the trends transforming APAC CRO
industry
P86A-52 June 2015
2P86A-52
Table of Contents
Section Slide Numbers
Executive Summary 10
• Key Findings 11
• Total CRO Market Size – By Stages of Clinical Development 16
• Market Size Estimation Methodology 17
• Scope and Segmentation 18
• Key Questions This Study Will Answer 19
• Total CRO Market Engineering Measurements 20
• CEO’s Perspective 21
• Key Companies to Watch 22
• 3 Big Predictions 24
Market Overview 26
• R&D Spending – Pharmaceutical Drug Development 27
• Market Perspective 28
• R&D Market Landscape 29
3P86A-52
Table of Contents
Section Slide Numbers
• CRO Product Development & Commercialization 30
• Total CRO Market Segmentation – By Stages of Clinical Development 31
• Total CRO Market Segmentation – By Therapeutic Services 32
• Key Market Trends 33
• eClinical solutions – An Overview 34
• eClinical solutions – Applications & Technologies 35
• Rise of Virtual Business Models 36
Competitive Playbook 37
• New Market Opportunities 38
• Merger, Acquisition, and Partnership Assessment 42
• Competitive Matrix 44
Drivers, Restraints, and Trends 45
• Market Drivers 46
• Market Restraints 47
4P86A-52
Table of Contents
Section Slide Numbers
Forecasts and Trends – Total Market 48
• Forecast Assumptions 49
• Total CRO Market Engineering Measurements 50
• Total CRO Market – Revenue Forecast 52
• Total CRO Market – Revenue Forecast Discussion 53
• Key Market Trends 54
• Key Market Trends Explained 55
Competitive Environment 58
• Competitive Analysis – Market Share 59
• Market Share Analysis 60
• Competitive Environment 61
• Competitive Analysis – Selected Key Market Participants 62
5P86A-52
Section Slide Numbers
CRO Segment Analysis 70
• Pre-clinical Trials Segment 71
• Segment Overview 72
• Market Engineering Measurements 73
• Revenue Forecast 74
• Key Trends 76
• Phase I Trials Segment 77
• Segment Overview 78
• Market Engineering Measurements 79
• Revenue Forecast 80
• Key Trends 82
• Phase II Trials Segment 83
• Segment Overview 84
Table of Contents (continued)
6P86A-52
Section Slide Numbers
• Market Engineering Measurements 85
• Revenue Forecast 86
• Key Trends 88
• Phase III Trials Segment 89
• Segment Overview 90
• Market Engineering Measurements 91
• Revenue Forecast 92
• Key Trends 94
• Phase IV Trials Segment 95
• Segment Overview 96
• Market Engineering Measurements 97
• Revenue Forecast 98
• Key Trends 100
Table of Contents (continued)
7P86A-52
Section Slide Numbers
• Data Management Segment 101
• Segment Overview 102
• Market Engineering Measurements 103
• Revenue Forecast 104
• Key Trends 106
• Biostatistics Segment 107
• Segment Overview 108
• Market Engineering Measurements 109
• Revenue Forecast 110
• Key Trends 112
• Pharmacovigilance Segment 113
• Segment Overview 114
• Market Engineering Measurements 115
Table of Contents (continued)
8P86A-52
Section Slide Numbers
• Revenue Forecast 116
• Key Trends 118
• Health Economics & Outcomes Research (HEOR) Segment 119
• Segment Overview 120
• Market Engineering Measurements 121
• Revenue Forecast 122
• Key Trends 124
• Bioanalytics Segment 125
• Segment Overview 126
• Market Engineering Measurements 127
• Revenue Forecast 128
• Key Trends 130
• Central Laboratory Services Segment 131
Table of Contents (continued)
9P86A-52
Section Slide Numbers
• Segment Overview 132
• Market Engineering Measurements 133
• Revenue Forecast 134
• Key Trends 136
The Last Word 137
Legal Disclaimer 140
Appendix 141
Table of Contents (continued)
10P86A-52
Market Size Estimation Methodology
Frost & Sullivan followed a three-step methodology to develop the analysis:
The information above was analysed and aggregated to produce this research service.
Frost & Sullivan uses the expertise of the global research staff
supported by the internal databases to develop insights into the
contract research market.
Secondary research is utilised to develop a baseline understanding of
the contract research industries as well as to identify key stakeholders
for the primary research phase.
Approximately 80 percent to 90 percent of the data provided in the
primary research is focused on obtaining targeted information from key
market participants by means of telephone and face to face interviews.
2. Secondary Research
3. Primary Research
1. Internal Expertise
Source: Frost & Sullivan
11P86A-52
Scope and Segmentation
Scope
Geographic coverage Asia Pacific
Study period 2014–2019
Base year 2014
Forecast period 2015–2019
Monetary unit US Dollars
This research service analyses the APAC clinical trials and research outsourcing (CRO) market.
It provides revenue forecasts for CROs in Asia Pacific by phase, therapeutic type and country.
The research study addresses the major issues and challenges, unmet needs and emerging trends in the market. Also, outlines market drivers and restraints and R&D trends.
Source: Frost & Sullivan
12P86A-52
Key Questions This Study Will Answer
How will contract research outsourcing help in drug development by saving time and cost for manufacturers?
What is the impact of the market growth in different regions?
Who are the predominant market participants in the CRO market and their market share contribution?
What are the key market trends observed towards expansion of contract research organizations in drug development across key therapeutic areas?
Are the products/services offered today meeting customer needs or is additional development needed?
What are the key market segments to look out for and what are the key trends followed in the market?
Source: Frost & Sullivan
13P86A-52
CRO Product Development & Commercialization
Source: Frost & Sullivan
Pre-clinical
Product Development Approval
Health Economic and outcome research (HEOR)
Phase I Phase II Phase III Phase IV
Central Laboratory Services
Biostatistics
Data Management
Late PhaseInterventional
Late PhaseObservational
Late Phase Pharmacovigilance
Other HealthcareSolutions
Commercialization
Bio-analyticsBio-analytics
Total CRO Market: Stages of Clinical Development, APAC, 2014
14P86A-52
Demand for new and effective
medication
Growing IT-enabled offerings
Data analytics to
witness radical growth
Evolving regulations
Quick time to market
model
Increase in laboratory
testing outsourcing
Demand for late-stage
development services
Central hub for novel
drug delivery
For detailed version, click here.
Key Market Trends
Rapid Consolidation
through strategic
M&As
Source: Frost & Sullivan
15P86A-52
CEO’s Perspective
2
Originator companies to conduct more local
studies in order to generate pharmaco-
economic data to support the listing of
medical impairments (blue book listing).
3eClinical technologies will completely
transform the way data management is being
carried out today.
4Regulatory co-operation in the Asia region
will offers the prospect of greater
harmonisation on clinical trial requirements.
1Global CROs will continue to merge or
acquire local CROs as a strategic means to
establish their presence in Asia Pacific
Source: Frost & Sullivan
5Co-drug development model will be the future
of drug development industry
16P86A-52
Sample of Key Highlights
• The Asia Pacific CRO market was $XXX billion in 2014 and is expected to reach $XXX billion in
2019, growing at a robust CAGR of XXX% from 2014 to 2019.
• APAC holds the third largest share of the CRO market and held XXX per cent share of the total
global CRO market in 2014.
• The share of services, such as Data management, Biostatistics, Health Economics and Outcomes
Research and Central Laboratory Services, is expected to grow at a double digit rate in next 5-6
years.
• Geographic outsourcing to low-cost locations is likely to result in lesser margins in the short term,
but higher volume share. However, with increased capacity and scale, companies are expected to
improve their margins during rest of the forecast period.
• Specialized services such as eClinical trial solutions, adaptive trial designs and outcomes research
are expected to transform the way clinical trials are performed today.
• Asia Pacific is experiencing tremendous growth in R&D spending, driven by increased globalization
of the pharmaceutical and biotechnology markets and low-cost advantage, which supports volume
growth.
Source: Frost & Sullivan analysis.
17P86A-52
Partial List of Companies Interviewed
• CMIC Co. Ltd
• Covance, Inc.
• CliniTech
• InVentiv health
• INC Research
• LSK Global Pharma Service
• Novotech (Australia) Pty Ltd
• PAREXEL International
• Pharmaceutical Product Development
(PPD)
• PhaseON Clinical Research Pvt. Ltd
• PRA International
Source: Frost & Sullivan research.
• QUANTICATE LTD
• Quintiles
• SGS Life Sciences
• Tigermed Consulting Ltd.
• WuXi PharmaTech